5,663 Shares in Novartis AG (NVS) Acquired by Valeo Financial Advisors LLC
Valeo Financial Advisors LLC acquired a new stake in Novartis AG (NYSE:NVS) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 5,663 shares of the company’s stock, valued at approximately $486,000.
Other large investors have also recently modified their holdings of the company. Farr Miller & Washington LLC DC raised its position in shares of Novartis by 0.3% during the 2nd quarter. Farr Miller & Washington LLC DC now owns 2,959 shares of the company’s stock worth $247,000 after buying an additional 10 shares in the last quarter. FCG Advisors LLC raised its position in shares of Novartis by 0.3% during the 2nd quarter. FCG Advisors LLC now owns 4,271 shares of the company’s stock worth $357,000 after buying an additional 12 shares in the last quarter. Parkside Financial Bank & Trust raised its position in shares of Novartis by 0.7% during the 2nd quarter. Parkside Financial Bank & Trust now owns 4,492 shares of the company’s stock worth $375,000 after buying an additional 31 shares in the last quarter. Brookstone Capital Management raised its position in shares of Novartis by 1.1% during the 2nd quarter. Brookstone Capital Management now owns 2,930 shares of the company’s stock worth $245,000 after buying an additional 31 shares in the last quarter. Finally, Newman Dignan & Sheerar Inc. raised its position in shares of Novartis by 1.0% during the 2nd quarter. Newman Dignan & Sheerar Inc. now owns 4,027 shares of the company’s stock worth $336,000 after buying an additional 40 shares in the last quarter. Hedge funds and other institutional investors own 10.87% of the company’s stock.
A number of analysts have commented on NVS shares. Zacks Investment Research upgraded shares of Novartis from a “hold” rating to a “buy” rating and set a $96.00 price target on the stock in a research report on Tuesday, September 19th. BidaskClub upgraded shares of Novartis from a “sell” rating to a “hold” rating in a research report on Saturday, August 19th. Leerink Swann boosted their price target on shares of Novartis from $89.00 to $91.00 and gave the stock a “market perform” rating in a research report on Monday, October 23rd. Finally, J P Morgan Chase & Co restated a “neutral” rating on shares of Novartis in a research report on Tuesday, October 10th. Four equities research analysts have rated the stock with a sell rating, ten have given a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Hold” and an average target price of $85.32.
Shares of Novartis AG (NYSE:NVS) traded down $0.16 on Tuesday, hitting $83.80. 1,126,400 shares of the stock traded hands, compared to its average volume of 2,259,253. The firm has a market cap of $198,615.36, a PE ratio of 17.68, a P/E/G ratio of 2.67 and a beta of 0.73. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.08 and a quick ratio of 0.81. Novartis AG has a 12 month low of $69.01 and a 12 month high of $86.90.
Novartis (NYSE:NVS) last announced its quarterly earnings data on Tuesday, October 24th. The company reported $1.29 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.25 by $0.04. The company had revenue of $12.41 billion for the quarter, compared to analysts’ expectations of $12.21 billion. Novartis had a net margin of 13.73% and a return on equity of 15.77%. The business’s revenue was up 2.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.23 EPS. equities research analysts forecast that Novartis AG will post 4.75 earnings per share for the current fiscal year.
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with Analyst Ratings Network's FREE daily email newsletter.